Cancer immunotherapy: accomplishments to date and future promise

作者: Karim Y Helmy , Shyam A Patel , George R Nahas , Pranela Rameshwar

DOI: 10.4155/TDE.13.88

关键词:

摘要: Cancer remains a devastating disease as existing therapies are too often ineffective and toxicities remain unacceptably high. Immunotherapies for cancer offer the promise of specificity memory immune system against malignant cells to achieve durable cure with minimal toxicity. Beginning success bone marrow transplantation blood-borne cancers, more recent development monoclonal antibody therapeutics variety tumors, immunotherapies already among most successful class treatments cancer. Greater understanding immunoregulatory mechanisms improved techniques cell manipulation engineering have led new immunomodulatory approaches cell-based that generated great excitement within biomedical community. As these technologies continue improve, harnessing power developed, will play an increasingly important role in treatment Here, we review history discuss emerging immunotherapy hope translate into clinical reality.

参考文章(118)
ROLF KIESSLING, NATURAL KILLER CELLS IN THE MOUSE The Role of Products of the Histocompatibility Gene Complex in Immune Responses. pp. 77- 85 ,(1976) , 10.1016/B978-0-12-401660-6.50012-6
William Coley, The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clinical Orthopaedics and Related Research. ,vol. 262, pp. 3- 11 ,(1991)
Robin J Prestwich, Fiona Errington, Kevin J. Harrington, Hardev S. Pandha, Peter Selby, Alan Melcher, Oncolytic viruses: do they have a role in anti-cancer therapy? Clinical Medicine: Oncology. ,vol. 2, pp. 83- 96 ,(2008) , 10.4137/CMO.S416
Daniel F. Graziano, Olivera J. Finn, Tumor Antigens and Tumor Antigen Discovery Cancer Treatment and Research. ,vol. 123, pp. 89- 111 ,(2005) , 10.1007/0-387-27545-2_4
Frank H. Valone, Eric Small, Patrick Burch, Reiner Laus, Madhusudan V. Peshwa, Malcolm Mackenzie, Martha Lacy, Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer Journal. ,vol. 7, ,(2001)
Juhua Zhou, Xinglei Shen, Jianping Huang, Richard J. Hodes, Steven A. Rosenberg, Paul F. Robbins, Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy Journal of Immunology. ,vol. 175, pp. 7046- 7052 ,(2005) , 10.4049/JIMMUNOL.175.10.7046
Elise Olsen, Madeleine Duvic, Arthur Frankel, Youn Kim, Ann Martin, Eric Vonderheid, Brian Jegasothy, Gary Wood, Michael Gordon, Peter Heald, Allan Oseroff, Lauren Pinter-Brown, Glen Bowen, Timothy Kuzel, David Fivenson, Francine Foss, Michael Glode, Arturo Molina, Elizabeth Knobler, Stanford Stewart, Kevin Cooper, Seth Stevens, Fiona Craig, James Reuben, Patricia Bacha, Jean Nichols, Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma Journal of Clinical Oncology. ,vol. 19, pp. 376- 388 ,(2001) , 10.1200/JCO.2001.19.2.376
Ronald B. Herberman, Robert K. Oldham, Evaluation of Cell-Mediated Cytotoxic Reactivity Against Tumor Associated Antigens with 125I-Iododeoxyuridine Labeled Target Cells Journal of Immunology. ,vol. 111, pp. 862- 871 ,(1973)
Shannon P. Hilchey, Ollivier Hyrien, Tim R. Mosmann, Alexandra M. Livingstone, Jonathan W. Friedberg, Faith Young, Richard I. Fisher, Raymond J. Kelleher, Richard B. Bankert, Steven H. Bernstein, Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab Blood. ,vol. 113, pp. 3809- 3812 ,(2009) , 10.1182/BLOOD-2008-10-185280
G. B. Challis, H. J. Stam, The Spontaneous Regression of Cancer: A review of cases from 1900 to 1987 Acta Oncologica. ,vol. 29, pp. 545- 550 ,(1990) , 10.3109/02841869009090048